Recurrent mutations in topoisomerase 2a cause a novel mutator phenotype in human cancers
Abstract
Topoisomerases are essential for genome stability. Here, we link the p.K743N mutation in topoisomerase TOP2A to a previously undescribed mutator phenotype in human cancers. This phenotype primarily generates a distinctive pattern of duplications of 2 to 4 base pairs and deletions of 6 to 8 base pairs, which we call ID_TOP2A. All tumors carrying the TOP2A p.K743N mutation showed ID_TOP2A, which was absent in all of 12,269 other tumors. We also report evidence of structural variation associated with TOP2A p.K743N. All tumors with ID_TOP2A mutagenesis had several indels in known cancer genes, including frameshift mutations in PTEN and TP53 and an in-frame activating mutation in BRAF. Thus, ID_TOP2A mutagenesis almost certainly contributed to tumorigenesis in these tumors. This is the first report of topoisomerase-associated mutagenesis in human cancers, and sheds further light on TOP2As role in genome maintenance. We also postulate that tumors showing ID_TOP2A mutagenesis might be especially sensitive to topoisomerase inhibitors.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Topoisomerase IIb binding underlies frequently mutated elements in cancer genomes
Liis Uusküla-Reimand, Christian A. Lee, … Jüri Reimand·Nature CommunicationsPeer-reviewed·Nov 21, 2025
- Trapped Topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast
Nicole Stantial, Anna T. Rogojina, … John L. Nitiss·Proceedings of the National Academy of SciencesPeer-reviewed·Oct 12, 2020
- A multi-species toolkit of TOP2 hypercleavage mutants for studying topoisomerase II-mediated DNA damage
David Ontoso, Monika Mehta, … Scott Keeney·Proceedings of the National Academy of SciencesPeer-reviewed·Sep 1, 2026
- Systematic Generation of Mutations at Topoisomerase II Cleavage Sites Enables Cancer Adaptation to Doxorubicin Therapy
Valid Gahramanov, Anjana Edathil Kadangodan, … Michael Y. Sherman·bioRxiv·Aug 21, 2026
- Genome-scale genetic interactions position the Mitotic Exit Network as a major antagonist of transient Topoisomerase II deficiency.
Cristina Ramos-Pérez, Jessel Ayra‐Plasencia, … Félix Machín·G3 Genes Genomes GeneticsPeer-reviewed·Aug 24, 2017
- KMT2C deficiency promotes APOBEC mutagenesis and genomic instability in multiple cancers